Predictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors

PURPOSE: Combinations of immune-checkpoint inhibitors (ICI) with other cancer therapies have been approved for advanced cancers in multiple indications, and numerous trials are under way to test new combinations. However, the mechanisms that account for the superiority of approved ICI combinations r...

Descripción completa

Detalles Bibliográficos
Autores principales: Palmer, Adam C., Izar, Benjamin, Hwangbo, Haeun, Sorger, Peter K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Translational Cancer Mechanisms and Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068233/
https://www.ncbi.nlm.nih.gov/pubmed/35045958
http://dx.doi.org/10.1158/1078-0432.CCR-21-2275

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068233/
https://www.ncbi.nlm.nih.gov/pubmed/35045958
http://dx.doi.org/10.1158/1078-0432.CCR-21-2275

Ejemplares similares